TransCode Therapeutics (RNAZ) Competitors $11.42 +0.19 (+1.69%) As of 11:32 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNAZ vs. MRSN, SNTI, DYAI, JATT, RENB, OKUR, ITRM, MAAQ, RVPH, and KZRShould you be buying TransCode Therapeutics stock or one of its competitors? The main competitors of TransCode Therapeutics include Mersana Therapeutics (MRSN), Senti Biosciences (SNTI), Dyadic International (DYAI), JATT Acquisition (JATT), Renovaro (RENB), OnKure Therapeutics (OKUR), Iterum Therapeutics (ITRM), Mana Capital Acquisition (MAAQ), Reviva Pharmaceuticals (RVPH), and Kezar Life Sciences (KZR). These companies are all part of the "pharmaceutical products" industry. TransCode Therapeutics vs. Its Competitors Mersana Therapeutics Senti Biosciences Dyadic International JATT Acquisition Renovaro OnKure Therapeutics Iterum Therapeutics Mana Capital Acquisition Reviva Pharmaceuticals Kezar Life Sciences TransCode Therapeutics (NASDAQ:RNAZ) and Mersana Therapeutics (NASDAQ:MRSN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends. Does the media prefer RNAZ or MRSN? In the previous week, Mersana Therapeutics had 3 more articles in the media than TransCode Therapeutics. MarketBeat recorded 3 mentions for Mersana Therapeutics and 0 mentions for TransCode Therapeutics. Mersana Therapeutics' average media sentiment score of 0.50 beat TransCode Therapeutics' score of 0.00 indicating that Mersana Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment TransCode Therapeutics Neutral Mersana Therapeutics Positive Which has more volatility & risk, RNAZ or MRSN? TransCode Therapeutics has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Comparatively, Mersana Therapeutics has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Which has preferable earnings and valuation, RNAZ or MRSN? TransCode Therapeutics has higher earnings, but lower revenue than Mersana Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTransCode TherapeuticsN/AN/A-$16.75MN/AN/AMersana Therapeutics$40.50M0.90-$69.19M-$14.62-0.50 Do insiders and institutionals believe in RNAZ or MRSN? 93.9% of Mersana Therapeutics shares are owned by institutional investors. 0.0% of TransCode Therapeutics shares are owned by company insiders. Comparatively, 13.0% of Mersana Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts rate RNAZ or MRSN? TransCode Therapeutics currently has a consensus target price of $280.00, indicating a potential upside of 2,351.84%. Mersana Therapeutics has a consensus target price of $56.60, indicating a potential upside of 673.75%. Given TransCode Therapeutics' higher possible upside, research analysts clearly believe TransCode Therapeutics is more favorable than Mersana Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransCode Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Mersana Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is RNAZ or MRSN more profitable? TransCode Therapeutics has a net margin of 0.00% compared to Mersana Therapeutics' net margin of -212.94%. TransCode Therapeutics' return on equity of -378.30% beat Mersana Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets TransCode TherapeuticsN/A -378.30% -186.01% Mersana Therapeutics -212.94%-990.16%-54.85% SummaryMersana Therapeutics beats TransCode Therapeutics on 7 of the 12 factors compared between the two stocks. Get TransCode Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAZ and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RNAZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNAZ vs. The Competition Export to ExcelMetricTransCode TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.48M$2.56B$5.78B$10.38BDividend YieldN/A57.29%5.74%4.64%P/E RatioN/A23.0977.0826.78Price / SalesN/A546.30507.10167.11Price / CashN/A169.7137.1760.63Price / Book-0.215.3713.696.40Net Income-$16.75M$32.95M$3.29B$271.62M7 Day Performance5.16%1.61%3.23%3.33%1 Month Performance16.53%7.76%8.37%10.15%1 Year Performance-99.90%-2.89%82.31%31.19% TransCode Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNAZTransCode Therapeutics1.7107 of 5 stars$11.42+1.7%$280.00+2,351.8%-99.9%$9.48MN/A0.009MRSNMersana Therapeutics4.1327 of 5 stars$7.17+0.4%$56.60+689.4%-86.1%$35.63M$40.50M-0.49150SNTISenti Biosciences3.2401 of 5 stars$1.36+0.7%$8.50+525.0%-55.0%$35.32M$2.56M-0.154News CoveragePositive NewsShort Interest ↓DYAIDyadic International2.8414 of 5 stars$0.97-0.1%$6.00+521.4%-15.4%$34.99M$3.49M-5.087Positive NewsGap UpJATTJATT AcquisitionN/A$2.00-1.0%N/A-51.0%$34.50MN/A0.003High Trading VolumeRENBRenovaro0.5023 of 5 stars$0.19-4.0%N/A-70.1%$34.20MN/A-0.2520Gap UpOKUROnKure Therapeutics2.8532 of 5 stars$2.39-2.4%$32.33+1,252.9%N/A$33.15MN/A-0.50N/ANews CoverageITRMIterum Therapeutics2.9997 of 5 stars$0.68+0.2%$9.00+1,215.8%-37.7%$32.19MN/A-0.8010News CoverageShort Interest ↓Gap UpMAAQMana Capital AcquisitionN/A$3.79-0.9%N/A+1,278.1%$30.79MN/A0.001RVPHReviva Pharmaceuticals2.9347 of 5 stars$0.43-2.3%$5.50+1,173.1%-69.6%$30.08MN/A-0.665News CoverageAnalyst ForecastGap DownKZRKezar Life Sciences3.6777 of 5 stars$3.91-1.0%$9.00+130.2%-34.8%$28.93MN/A-0.4060 Related Companies and Tools Related Companies Mersana Therapeutics Competitors Senti Biosciences Competitors Dyadic International Competitors JATT Acquisition Competitors Renovaro Competitors OnKure Therapeutics Competitors Iterum Therapeutics Competitors Mana Capital Acquisition Competitors Reviva Pharmaceuticals Competitors Kezar Life Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNAZ) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransCode Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransCode Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RNAZ Stock Alerts